Eyevensys is a technology company.
Eyevensys has raised $30.0M across 1 funding round.
Eyevensys has raised $30.0M in total across 1 funding round.
Eyevensys is a Paris-based, clinical-stage biotechnology company founded in 2008, specializing in a first-in-class, non-viral gene therapy platform for sustained drug delivery to treat major ophthalmic conditions like degenerative retinal diseases (e.g., wet and dry AMD), retinal vascular diseases, non-infectious uveitis, retinitis pigmentosa, and glaucoma[1][2][3][6]. The platform uses electroporation to deliver DNA plasmids into the ciliary muscle, enabling long-term intraocular production of therapeutic proteins such as anti-TNF (EYS606), anti-VEGF (EYS609), and neuroprotective agents (EYS611), addressing vision loss affecting millions globally by avoiding frequent injections, subretinal delivery, or implants[1][3][5]. It serves patients with blinding eye diseases, ophthalmologists, and the biotech ecosystem, with early clinical validation in uveitis and preclinical efficacy across models; the company raised funding from investors like Korea Investment Partners, Bpifrance, and Karista VC[1][2].
Note: Eyevensys pivoted and relaunched as PulseSight Therapeutics in 2024, retaining its core technology and IP to target dry AMD with PST-611 entering Phase I, driven by a COVID-induced pause that shifted focus to higher-market opportunities[2][8].
Eyevensys was founded in 2008 by Francine Béhar-Cohen, MD, PhD, a vitreoretinal surgeon and INSERM researcher with 23+ years studying ocular disease pathophysiology; she previously founded EyeGate Pharma[2][5]. The idea stemmed from her work developing electroporation-based delivery of DNA plasmids to the ciliary muscle for sustained protein production in the vitreous, initially targeting severe non-infectious uveitis after preclinical success in animal models (rats, rabbits) showing durable expression of anti-VEGF, anti-TNF, and neuroprotective proteins[2][3]. Early traction included clinical validation of the electro-transfection platform for uveitis (EYS606 in trials by 2019-2020), FDA-compliant device testing, and recognition in France's Tech 120 program[3][5][6]. Patricia Zilliox served as President & CEO around 2019, showcasing the pipeline at events like OIS@ASRS[3]. The COVID-19 pause led to a 2024 pivot to PulseSight under new CEO Judith Greciet, prioritizing dry AMD[2].
Eyevensys rides the wave of gene therapy innovation in ophthalmology, where retinal diseases like AMD drive majority of global vision loss, amid surging demand for durable, injection-free treatments amid aging populations and limitations of anti-VEGF standards (frequent dosing, poor dry AMD options)[1][2][3]. Timing aligns with non-viral tech maturation—electroporation offers viral vector alternatives' benefits (sustained efficacy) minus risks like immunogenicity, fitting post-COVID biotech pivots to high-value indications[2]. Market tailwinds include $20B+ AMD space, regulatory nods for gene therapies (e.g., Luxturna), and France's strong medtech ecosystem via INSERM/Bpifrance[1][5]. It influences by validating ciliary muscle as a "biofactory," potentially enabling platforms for other back-of-eye diseases and inspiring non-viral shifts.
Eyevensys' legacy endures via PulseSight, with Phase I dry AMD data as the pivotal near-term catalyst to de-risk the platform and attract partners/big pharma[2][8]. Trends like AI-optimized plasmids, combo therapies, and global AMD prevalence will propel it, potentially expanding to wet AMD/RP trials using EYS609/EYS611 assets. Influence may grow through licensing or acquisition, transforming it from uveitis pioneer to retinal gene therapy leader—watch for 2026 readouts tying back to its factory-like delivery solving injection fatigue.
Eyevensys has raised $30.0M in total across 1 funding round.
Eyevensys's investors include Pureos Bioventures.
Eyevensys has raised $30.0M across 1 funding round. Most recently, it raised $30.0M Series B in January 2020.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Jan 1, 2020 | $30.0M Series B | Pureos Bioventures |